These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 20391646)

  • 1. Use of ozone-depleting substances; removal of essential-use designation (flunisolide, etc.). Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2010 Apr; 75(71):19213-41. PubMed ID: 20391646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of ozone-depleting substances; removal of essential-use designations. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Apr; 70(63):17167-92. PubMed ID: 15806739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of ozone-depleting substances; removal of essential use designations; confirmation of effective date. Direct final rule; confirmation of effective date.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Apr; 72(81):20942. PubMed ID: 17520770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of Ozone-Depleting Substances. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2016 Oct; 81(207):74298-302. PubMed ID: 27905700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of nebulized flunisolide combined with salbutamol and ipratropium bromide in stable patients with moderate-to-severe chronic obstructive pulmonary disease.
    Paggiaro PL; Vagaggini B; Di Franco A; Zingoni M; Fano M; Biraghi M
    Respiration; 2006; 73(5):603-9. PubMed ID: 16293958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new beginning: making way for CFC-free inhalers.
    Weller T
    Community Nurse; 1998 Nov; 4(10):23-4. PubMed ID: 10326377
    [No Abstract]   [Full Text] [Related]  

  • 7. Delivery of ipratropium and albuterol combination therapy for chronic obstructive pulmonary disease: effectiveness of a two-in-one inhaler versus separate inhalers.
    Chrischilles E; Gilden D; Kubisiak J; Rubenstein L; Shah H
    Am J Manag Care; 2002 Oct; 8(10):902-11. PubMed ID: 12395958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhalation solutions: which one are allowed to be mixed? Physico-chemical compatibility of drug solutions in nebulizers.
    Kamin W; Schwabe A; Krämer I
    J Cyst Fibros; 2006 Dec; 5(4):205-13. PubMed ID: 16678502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economics of "essential use exemptions" for metered-dose inhalers under the Montreal Protocol.
    DeCanio SJ; Norman CS
    J Environ Manage; 2007 Oct; 85(1):1-8. PubMed ID: 16982135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The change to non-CFC metered dose inhalers.
    Rubinfeld A
    Aust Fam Physician; 1997 Dec; 26(12):1412-4. PubMed ID: 9470296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asthma/Allergy. FDA advises asthma patients to switch to new Albuterol inhalers.
    Child Health Alert; 2008 Sep; 26():5. PubMed ID: 18953699
    [No Abstract]   [Full Text] [Related]  

  • 12. Final rule on albuterol inhalers.
    FDA Consum; 2005; 39(4):3. PubMed ID: 16255065
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and safety of eco-friendly inhalers: focus on combination ipratropium bromide and albuterol in chronic obstructive pulmonary disease.
    Panos RJ
    Int J Chron Obstruct Pulmon Dis; 2013; 8():221-30. PubMed ID: 23658481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increasing compliance with inhaled corticosteroids through the use of combination therapy.
    Holt S; Masoli M; Beasley R
    J Allergy Clin Immunol; 2004 Feb; 113(2):219-20. PubMed ID: 14767433
    [No Abstract]   [Full Text] [Related]  

  • 15. Metering performance of several metered-dose inhalers with different spacers/holding chambers.
    Berlinski A; Waldrep JC
    J Aerosol Med; 2001; 14(4):427-32. PubMed ID: 11791683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pulmonary disease.
    Balkissoon R; Make B
    COPD; 2008 Aug; 5(4):221-7. PubMed ID: 18671147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use; final monograph for combination drug products. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 Dec; 67(246):78158-72. PubMed ID: 12508820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhalation therapy with metered-dose inhalers and dry powder inhalers in mechanically ventilated patients.
    Dhand R
    Respir Care; 2005 Oct; 50(10):1331-4; discussion 1344-5. PubMed ID: 16185369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Final count down to hfa albuterol inhalers: are we ready as yet?
    Butt AT; Kamat D; Pansare M
    Clin Pediatr (Phila); 2009 Mar; 48(2):131-4. PubMed ID: 19015282
    [No Abstract]   [Full Text] [Related]  

  • 20. The president speaks: prevention is best: lessons from protecting the ozone layer.
    Woodcock A
    Thorax; 2012 Dec; 67(12):1028-31. PubMed ID: 23019254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.